Patent application number | Description | Published |
20100092294 | HELICOPTER ANTITORQUE TAIL ROTOR - A blade for an antitorque tail rotor of a helicopter, having a leading edge and a trailing edge opposite each other and elongated along a longitudinal axis of the blade; the trailing edge, in use, interacts with the air current after the leading edge; the blade also has two opposite surfaces extending between the leading edge and the trailing edge, and a root portion extending from a radially inner first end, with respect to a rotation axis of the blade, towards a second end opposite the first end; and the root portion, when sectioned in a plane perpendicular to the leading edge and trailing edge, has a profile asymmetrical with respect to a chord joining the leading edge and trailing edge. | 04-15-2010 |
20100092299 | HELICOPTER ANTITORQUE TAIL ROTOR BLADE - A blade for an antitorque tail rotor of a helicopter, having a leading edge and a trailing edge opposite each other and elongated along a longitudinal axis of the blade; the trailing edge, in use, interacts with the air current after the leading edge; the blade also has an end portion extending between a reference section and a radially outer end of the blade with respect to a rotation axis of the blade; the rotation axis is outside the blade and crosswise with respect to the longitudinal axis; the length of the chord at the end portion decreases from the reference section to the radially outer end; and the leading and trailing edges are joined at the radially outer end. | 04-15-2010 |
Patent application number | Description | Published |
20100104563 | ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY - Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental. | 04-29-2010 |
20110008357 | ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY - Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental. | 01-13-2011 |
20130101595 | ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY - Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental. | 04-25-2013 |